VIDEO: Study focuses on GA lesion growth with monthly pegcetacoplan, avacincaptad pegol
Click Here to Manage Email Alerts
SEATTLE — In this video, Eleonora M. Lad, MD, PhD, discusses presentations from the ARVO annual meeting on real-world use of faricimab and the use of pegcetacoplan in the treatment of geographic atrophy.
A notable presentation on the last day of the meeting evaluated the use of pegcetacoplan vs. avacincaptad pegol in geographic atrophy, according to Lad, vice chair of ophthalmology clinical research at Duke Health.
The analysis suggested a greater reduction in geographic atrophy lesion growth with monthly pegcetacoplan vs. monthly avacincaptad pegol.
Lad said this research is important because “we often have both drugs available to us, and as clinicians, we struggle to know which one to use.”
Reference:
- Zarbin MA, et al. Pegcetacoplan vs avacincaptad pegol in geographic atrophy: an anchored matching-adjusted indirect comparison of three phase 3 trials. Presented at: Association for Research in Vision and Ophthalmology meeting; May 5-9, 2024; Seattle.
Collapse
Healio Interviews
Click Here to Manage Email Alerts